newsfilter
← Latest News
Earnings Call Transcripts·

Auna 3Q26 Conference Call - AUNA SA

  • Financial Performance:

    • Total revenue grew 10% year-over-year on an FX-neutral basis.
    • Consolidated free cash flow surged 95% year-to-date to S/626 million; net operating cash flow rose 62% to S/713 million.
    • Leverage ratio improved sequentially to 3.5x net debt/EBITDA, trending toward a medium-term target of 3.0x.
    • Adjusted EBITDA declined due to extraordinary items: Colombia faced S/40 million in adverse oncology costs (approx. 4% of revenue) and Peru absorbed S/18 million in prior-year billing adjustments. Excluding these, Peru's EBITDA remained stable and Mexico's grew 5%.
    • Adjusted net income decreased primarily due to the absence of a S/40 million non-cash FX gain recorded in Q3 2025; underlying net finance costs improved to a blended rate of 10.38%.
    • Capital expenditures remained at 3% of revenue, below the 4% full-year guidance.
    • Cash conversion cycle improved from negative 9 days in 2025 to negative 15 days.
  • Guidance and Future Outlook:

    • Full-year 2026 revenue growth guidance remains 10% to 14% (FX-neutral).
    • Full-year 2026 adjusted EBITDA guidance remains broadly stable or slightly down year-over-year, reflecting one-off Colombia oncology costs and ongoing regulatory price cap impacts.
    • Capex guidance remains unchanged at approximately 4% of consolidated revenues.
    • Peru profitability is expected to improve in the second half of 2027 as billing reconciliations normalize and new B2B account utilization levels off.
    • Mexico is projected to continue accelerating growth and margin expansion in Q4 and beyond.
    • Colombia is expected to gradually recover profitability once the terminated contract is fully off-book and price cap impacts stabilize.
  • Business Segments and Product Lines:

    • Mexico: Surgery volumes up 12% and oncology sessions (chemo/radio) up 34%; EBITDA grew 5% YoY despite industry-wide VAT deductibility headwinds. AUNA Seguros faced headwinds, but the Monterrey healthcare network grew EBITDA 10%.
    • Peru: Surgery volumes up 21% and chemo/radio up 18%; EBITDA declined 6% excluding billing penalties. OncoSalud MLR stands at 50.7%. New corporate agreements will add 4,000 members in Q4.
    • Colombia: Revenue grew 12% in local currency; EBITDA declined 30% due to an unprofitable oncology risk-sharing contract (terminated) and regulatory price caps on high-cost medications. Private payer revenues increased 22%.
    • Strategic Initiatives: Expansion of high-complexity care (neurosurgery, orthopedics, cardiovascular) in Peru; Centro Ambulatorio Treca construction in Peru is on schedule.
    • B2G Partnerships: Active progress on a potential partnership with SOGIE (Peru) and the Torre Treca public-private project.
  • Market and Competitive Landscape:

    • Mexico's insurance market faced a 15-year low in policyholders due to VAT regulations, yet AUNA gained market share by offering competitive pricing to insurers.
    • Colombia faces structural pressure from statutory wage increases and regulatory price caps, driving a strategic shift toward private payers and high-complexity care.
    • Peru remains focused on high-margin B2B corporate accounts and asset-light expansion to increase capacity without heavy capital expenditure.
    • AUNA continues to leverage its integrated model to capture high-complexity care volumes across the region.
  • Risks and Challenges:

    • Colombia: Specific oncology risk-sharing contract incurred costs far exceeding assumptions (4% of revenue); regulatory price caps on oncology drugs impacting margins into Q4.
    • Peru: Ongoing reconciliation of prior-year receivables affecting near-term earnings; high operational costs due to hospitalization and emergency volumes.
    • Regulatory: Price caps in Colombia and VAT deductibility changes in Mexico.
    • Environmental: Potential impact of a strong "El Niño" phenomenon; operational continuity plans activated for infrastructure and supply chain.
    • Financial: FX exposure and debt maturity profiles (S/481m due in 12 months, well-covered by credit lines and cash).
  • Management Commentary and Tone:

    • Management acknowledged a "tough quarter" with extraordinary, unexpected headwinds in Colombia and Peru but emphasized strong underlying fundamentals.
    • Tone is confident regarding long-term regional potential, specifically highlighting Mexico's momentum and the strategic pivot in Colombia.
    • Executives emphasized a commitment to predictability and controlling qualitative results to eliminate "surprises" for investors.
    • Highlighted successful risk mitigation, such as the termination of the problematic Colombia contract and the robust response to the Pope's visit in Peru as a testament to operational capability.
  • Analyst Questions and Answers:

    • Colombia Contract: Management confirmed the adverse oncology contract was an isolated incident with no expected contagion to other PGP/PIP contracts; the contract has been terminated.
    • Mexico Utilization: Target utilization growth is projected at 2-3% annually; Monterrey network operates at 41% utilization with EBITDA margins of 28%, with room for further expansion.
    • Peru Billing: Management expects billing reconciliation impacts to normalize by the second half of 2027 following improved internal billing cycles.
    • El Niño: Specific contingency plans activated for fuel, water, power, and patient flow continuity across the Peru network.
    • Bond Maturity: Approximately $100 million of 2029 bonds outstanding; callable at 105% at year-end, with refinancing options under constant review.
  • Other Key Points:

    • AUNA Seguros in Mexico is pivoting to focus on B2B dental/vision and potential oncology insurance products.
    • The company successfully managed the Pope's visit in Peru, demonstrating high-capacity operational readiness.
    • 80% of Mexico's payer relationships have confirmed operating tiers; out-of-pocket revenue share is growing from 6% to ~9%.
    • 54% of gross debt is in local currency, with 85% of USD-denominated debt hedged against the Sol and 75% of Mexican floating debt hedged.
    • The "asset-light" strategy is being aggressively pursued in Peru and Colombia to expand high-complexity outpatient services.
Company
AUNA SA
Keywords
AUNA SA